SOUTH SAN FRANCISCO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) announced that the Company will host the muscle biology-focused Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) today, May 17th, 2024 at the Mission Bay Conference Center in San Francisco. This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update the ...

SOUTH SAN FRANCISCO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) announced that the Company will host the muscle biology-focused Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) today, May 17th, 2024 at the Mission Bay Conference Center in San Francisco. "We are proud to convene the CLIMB Research Symposium, a unique forum for the muscle biology community, including academic researchers and students, to engage in scientific discussion and share inno ...

Title: Effect of Aficamten on Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy: The SEQUOIA-HCM CMR Substudy Presenter: Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University Date: Augst 30, 2024 Topic: Infiltrative Myocardial Disease Session Title: Cardiac Amyloidosis: Diagnosis and Outcomes Session Type: Moderated ePosters Session Time: 3:00-3:50 PM BST Location: Station 10 Title: Clinical Application of Biomarkers in ...

Analyses of SEQUOIA-HCM Elaborate on Dosing and Measures of Safety During Treatment with Aficamten Results from Cardiopulmonary Exercise Testing Showed Improvement in Exercise Performance were Strongly Correlated to Other Measures of Clinical Improvement Company to Host Investor Event and Webcast Today at 4:00 PM Western European Summer Time (11:00 AM Eastern Time) SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that additional results ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50633 CYTOKINETICS, INCORPORATED (Exact name of registrant as specified in its charter) Delaware 94-3291317 (State or other jur ...

Diane Weiser - SVP of Corporate Communication and IR Robert Blum - President and CEO Fady Malik - EVP of R&D Stuart Kupfer - SVP and Chief Medical Officer Andrew Callos - EVP and Chief Commercial Officer Robert Wong - VP and Chief Accounting Officer Good afternoon. And welcome ladies and gentlemen to Cytokinetics First Quarter 2024 Conference Call. [Operator Instructions] Good afternoon. And thanks for joining us on the call today. Robert Blum, President and Chief Executive Officer, will begin with an overv ...

Cytokinetics (CYTK) came out with a quarterly loss of $1.33 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -14.66%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $1.03 per share when it actually produced a loss of $1.38, delivering a surprise of -33.98%.Over the last four quarters, the com ...

SOUTH SAN FRANCISCO, Calif., May 8, 2024 - Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the first quarter of 2024. Net loss for the first quarter was $135.6 million, or $1.33 per share, compared to net loss for the first quarter of 2023 of $131.3 million, or $1.38 per share. Cash, cash equivalents and investments totaled $634.3 million at March 31, 2024. "In the first quarter, we advanced our muscle-biology portfolio anchored by the broad development program of aficamten. In para ...

Data Support Advancement to Phase 2 Clinical Trial in Patients with Heart Failure with Preserved Ejection Fraction Expected to Begin in Q4 2024 Full Data from the Phase 1 Study to be Presented at a Medical Congress in 2H 2024 SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced topline data from the Phase 1 study of CK-4021586 (CK-586). The study met its primary and secondary objectives to assess the safety, tolerability and pharmacokinetics ...

SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that on April 30, 2024 it granted stock options to purchase an aggregate of 29,646 shares of common stock and 17,012 shares of restricted stock units (RSUs) convertible into shares of common stock upon vesting to five new employees, whose employment commenced in April 2024, as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the fir ...